The median survival for patients with DMPM is between four and 12 months, depending on the stage at presentation. Standard management approaches have provided limited effectiveness. The literature on management has been revised, and the authors present their data on outcomes for 120 patients treated with an aggressive trimodality approach. An aggressive trimodality approach including extrapleural pneumonectomy followed by chemoradiation produces low mortality and acceptable morbidity. An optimal universal staging system is still awaiting definition and validation.
Prognosis is best for patients with localized disease and epithelial histology.
Several new investigational approaches are now being tested, including intrapleural interferon gamma, photodynamic therapy, immunotherapy, and gene therapy. If you have any questions regarding this new treatment or your legal rights, please contact us . If you have any questions regarding your legal rights, please contact us . All Rights Reserved.